Reported in this Northern Echo article. Susan White had osteomalacia, a very painful condition caused by vitamin D deficiency. Bones are weakened by this illness and so there is a greater risk of fractures.
Following two spinal fractures, Susan White's condition was mistakenly attributed to osteoporosis, but fortunately for her she later received the correct diagnosis of osteomalacia, for which the treatment is vitamin D. Like Susan White, I too suffered from osteomalacia many years ago, and like her, was told that it was osteoporosis and in consequence years later was put onto HRT, which caused me very great harm. I should of course have been treated with vitamin D for the osteomalacia, but Dr Nigel Bax actively sought to dissuade me even from taking vitamin D off my own bat. He thus set in train a disastrous accumulation of damage to my health. I'm pleased that Susan White has been spared a lot of unnecessary suffering by having her problem correctly diagnosed.
Thursday, January 21, 2010
Vitamin D treatment transformed Susan White's life.
Posted by
Willow
at
1:58 pm
Labels: Dr Nigel Bax, fragile bones, osteomalacia, osteoporosis, risk of fractures, spinal fractures, Vitamin D deficiency
Thursday, May 03, 2007
A new osteoporosis drug
Osteoporosis drug offers women hope - Telegraph
Extracts:
"Women who are given an annual treatment for post-menopausal osteoporosis are less likely to suffer a broken hip or other fractures than those taking daily or weekly pills, according to a study to be published today.
Patients given a drip into the back of the hand of zoledronic acid, sold as Aclasta, cut the risk of hip breaks by 41 per cent and spinal breaks by 70 per cent compared to patients given a placebo.
Around half a million women in the UK take drugs such as alendronate and risedronate, known as bisphosphonates, in pill form daily or weekly to treat post-menopausal osteoporosis.
However, around half of patients stop taking the pills within a year.
The National Osteoporosis Society estimates that more than 60,000 hip and 120,000 spinal fractures take place each year in the UK.
Approximately one in five people die within three months of breaking their hip, which accounts for around 14,000 deaths annually.
Bone density is reduced in patients with osteoporosis, leading to greater risk of fractures.
Hormonal changes during the menopause put women at greater risk."
"Writing in The New England Journal of Medicine, lead researcher Prof Dennis Black, of the University of California, San Francisco, said: "During a three-year period, an annual infusion of zoledronic acid significantly reduced the risk of fracture at all key osteoporotic fracture sites including vertebral and hip fractures.
"A regimen of infusions once a year appears to ensure that patients will have a full treatment effect for at least 12 months.
"In contrast, many patients who receive prescriptions for oral bisphosphonates stop treatment, and most appear to be taking less than 80 per cent of their prescribed pills by 12 months."
The researchers said the infusion reduced the risk of spinal fractures by significantly more than the daily and weekly pills currently in use. Novartis, the company that manufactures the drug, hopes it will be available in the UK by the autumn."
"However, an abnormal heart rhythm, which can increase the risk of a stroke, was nearly three times more common among the 3,889 volunteers who took the Novartis drug.
The most common side effects with Aclasta were fever, muscle pain, flu-like symptoms, headache, and bone pain."
Osteoporosis can also be caused or exacerbated by 'slimming'/dieting. Give up dieting! - Safeguard your bone density by eating good, healthy meals and cutting down on salt and salty food.
Lose weight by eating less salt! Go on! - Try it! - You will feel so much better!
See my website www.wildeaboutsteroids.co.uk
(The site does not sell anything and has no banners or sponsors or adverts - just helpful information.)
Posted by
Willow
at
3:03 pm
Labels: Aclasta, alendronate, Bone density, eat less salt, Novartis, oral bisphosphonates, osteoporosis, Prof Dennis Black, risedronate, side-effects, spinal fractures, zoledronic acid

